Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
- Genentech pays Hanmi up to $2.3bn for obesity drug
- Lupus Research Alliance Awards More Than $2 Million to Study the Power of Lifestyle Interventions
- Mirum Pharmaceuticals (MIRM) Following Rare Disease Growth Narrative Looks Undervalued
- Perez Hilton’s Brother-in-Law Shares Update on His Injuries, Mental Health Amid Hospitalization
- Here’s how VCU researchers are reviving the house call to treat teen obesity
- ATHX picks New York to throw down its HYROX gauntlet
- Vegetarian Diet and 14-Hour Fast Improve Type 2 Diabetes Control
- New York levels up funding for mental health ‘clubhouses’
Browsing: call
Hims & Hers Health, Inc.HIMS used its second-quarter 2026 call to frame AI, specialty expansion and international scale as growth drivers, while acknowledging gross-margin pressure from branded weight loss and overseas mix
Fractyl HealthGUTSsaid its Revita endoscopic procedure showed durable weight-maintenance results one year after patients discontinued GLP-1 therapy, while the company reaffirmed plans to report pivotal trial data in early fourth-quarter 2026 and pursue a potential FDA De Novo submission later in the year
Strong growth led by weight loss and international expansion: Q2 revenue rose nearly 40% year over year to more than $753 million, supported by 300,000 new subscribers and the Eucalyptus acquisition. Hims & Hers raised its 2026 revenue outlook to $3.1 billion–$3.3 billion
Top doctors call for junk food advertising ban, seek curbs on celebrity endorsements and sports sponsorships HomeLive TV Sections WorldEntertainmentExplainersCricketSportsOpinionIndiaTechAutoLifestyleHealthBusinessVideosImpact ShortsWeb Stories Shows VantageFirstpost AmericaFirstpost AfricaFirst SportsSpotlightLive TV Events FIFA World CupUnion BudgetIndependence DayDelhi Elections 2025
Weak second-quarter performance led Xponential Fitness to lower its 2026 outlook. North American same-store sales fell 6.8%, revenue declined 13% to $66 million, and adjusted EBITDA dropped 22% to $21.9 million
PerrigoPRGOreported second-quarter 2026 results that exceeded its internal earnings expectations, while sales declined amid soft consumer self-care categories, retailer inventory reductions and a slower start to seasonal demand. The company maintained its full-year outlook, citing improving category trends, market-share gains and expected second-half contributions from innovation, distribution and demand-generation efforts
Novo Nordisk A/SNVOreported second-quarter adjusted sales growth of 7% at constant exchange rates, supported by GLP-1 volume growth across its obesity and diabetes franchises, while lower realized prices and manufacturing-related costs weighed on margins
DoximityDOCSreported fiscal 2027 first-quarter revenue of $157 million, up 7% from a year earlier, as the company cited improving demand from pharmaceutical and hospital customers and increased engagement with its clinical artificial intelligence tools
The Africa Centres for Disease Control and Prevention (Africa CDC) and the World Health Organization (WHO) have called for an urgent scale-up of the community-led Ebola response in the Democratic Republic of the Congo (DRC), with stronger early detection, contact follow up, access to care, support for frontline health workers and faster delivery of re
Psychology says people who never take lunch breaks aren’t always the most productive

